Diasorin S.p.a. · MIL:DIA
Diasorin — 9M 2021 Earnings Presentation
16 slides from Diasorin's earnings presentation, Nov 11, 2021
Slide 1: 9M 2021 Results
9M 2021 RESULTS November 11, 2021
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements, including within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934. We intend the forward-looking statements contained in this document to be covered
Slide 4: Financial Highlights
Financial Highlights Change Change Data in €/mln Q3’21 9M’21 @ current @ CER @ current @ CER Revenues 343.5 50.7% +50.2% 858.9 +40.8% +43.6% CLIA ex Vitamin D +30.3% +29.2% +27.0% +28.6% Vitamin D (CLIA) -8.2% -8.7% +9.2% +12.4% ELISA tests -10.9% -11.2% -16.4% -14.2% Molecular tests +5.5% +5.4% +52
Slide 5: 9M 2021 key facts
9M 2021 key facts Business Development Convertible bond loan to complete the acquisition of Luminex • Luminex acquisition: the closing of the transaction is effective starting from July 14, 2021. • Placement of an unsecured equity-linked senior bond loan for € 500 million with maturity to Through th
Slide 6: Managerial outlook on Q3 and 9M 2021 revenues
Managerial outlook on Q3 and 9M 2021 revenues Total Q3 Group revenues at constant perimeter§ (data in €/mln) Total 9M Group revenues at constant perimeter§ (data in €/mln) Data @CER Data @CUR Data @CER Data @CUR +29% +26% +10% +11% 784 768 610 265 610 258 228 251 228 252 165 165 70 80 70 81 520 445
Slide 7: Q3 and 9M 2021 revenue growth by geography and technology
Q3 and 9M 2021 revenue growth by geography and technology Q3’21 vs. 9M’21 vs. Q3’21 vs. 9M’21 vs. BY GEOGRAPHY§ BY TECHNOLOGY§ Q3’20 9M’20 Q3’20 9M’20 EUROPE & AFRICA • Q3 & 9M: Positive top line trend, thanks to the contribution of COVID- +19.4% +31.7% reported +30.3% +27.0% 19 testing and the stro
Slide 8: 9M 2021 revenues breakdown
9M 2021 revenues breakdown BY GEOGRAPHY BY TECHNOLOGY Instruments & other revenues 9M’20 9.3% 9M'20 Molecular diagnostic tests USA & Canada 26.0% Europe & Africa CLIA tests 40.0% 45.2% 56.4% ELISA tests Asia Pacific 8.3% Latin America 11.2% 3.6% Luminex 10.6% USA & Canada Instruments & other revenue
Slide 9: Q3 and 9M'21 profitability profile
Q3 and 9M’21 profitability profile DATA IN €/MLN Q3'20 Q3'21 Change % 9M'20 9M'21 Change % GROSS PROFIT 155.7 224.5 +44.2% 419.7 579.9 +38.2% GROSS PROFIT MARGIN 68.3% 65.4% -294 bps 68.8% 67.5% -128 bps • Luminex acquisition had an expected dilutive ADJUSTED EBITDA* 104.1 139.2 +33.7% 257.7 383.2 +
Slide 10: New FY 2021 Company Guidance
New FY 2021 Company Guidance NEW FY 2021 GUIDANCE at 2020 CER: REVENUES: growth approx. 40%, ADJUSTED EBITDA* MARGIN: approx. 43% The expected growth in revenues at CER and constant perimeter of consolidation vs. FY’20 is approx. 18% *Adjusted EBITDA means EBITDA adjusted to exclude the one-off
Slide 11: Investor Day 2021 – December 17, 2021
Investor Day 2021 – December 17, 2021 @ Palazzo Mezzanotte - Milan 1:00 PM CET Welcome, Light Lunch and presentation of DiaSorin diagnostic platforms 2:00 PM CET Presentation of the strategic plan 3:45 PM CET Conclusion of the event Live streaming will be available on the website in the Investor Day
Slide 12: Financial schemes
Financial schemes 12
Slide 13: Income Statement
Income Statement Q3 Change 9 months Change (Amounts in million of euros) 2020 2021 amount % 2020 2021 amount % Net Revenues 227.9 343.5 +115.6 +50.7% 610.1 858.9 +248.8 +40.8% Cost of sales (72.2) (118.9) -46.7 +64.8% (190.4) (279.0) -88.6 +46.5% Gross profit 155.7 224.5 +68.9 +44.2% 419.7 579.9 +16
Slide 14: Balance Sheet
Balance Sheet (Amounts in million of euros) 12/31/2020 09/30/2021 Change Goodwill and intangibles assets 356.7 1,722.6 +1,365.9 Property, plant and equipment 140.5 268.0 +127.5 Other non-current assets 35.3 60.3 +25.0 Net working capital 217.9 345.4 +127.4 Other non-current liabilities (99.5) (108.8
Slide 15: Cash flow statement
Cash flow statement Q3 9 months (Amounts in million of euros) 2020 2021 2020 2021 Cash and cash equivalents at the beginning of the period 181.1 896.8 157.6 339.9 Cash provided by operating activities 49.6 127.5 105.4 301.1 Cash used in investing activities (15.5) (33.7) (31.4) (83.3) Cash provided/
Slide 16: DiaSorin
DiaSorin